Joëlle Vincent1,2,3, Marie-Kristelle Ross2,4,5, Neal W Pollock2,5,6. 1. Department of Medicine, Université Laval, Québec, Canada. 2. Service de Médecine Hyperbare, Hôtel-Dieu de Lévis, Québec, Canada. 3. Dr Joëlle Vincent, Department of medicine, Université Laval, 1050, avenue de la Médecine, Québec, QC, G1V 0A6, Canada, joelle.vincent.1@ulaval.ca. 4. Department of Cardiology, Hôtel-Dieu de Lévis, Québec, Canada. 5. Centre de médecine de plongée du Québec, Hôtel-Dieu de Lévis, Québec, Canada. 6. Department of Kinesiology, Université Laval, Quebec, Canada.
Abstract
INTRODUCTION: Hyperbaric oxygen treatment (HBOT) is available to a wide spectrum of patients, many with significant co-morbidities. Considering its effects on cardiac physiology and reports of pulmonary oedema following exposure, concerns exist about the safety of patients with compromised cardiac function. Few studies have described adverse events occurring during HBOT and even fewer reports address events arising in the hours following HBOT. A relation between adverse events and cardiac function has not been established. As medical guidance is limited, we aimed to evaluate the risk for patients with reduced left ventricular ejection fraction (LVEF) receiving HBOT. METHODS: This retrospective chart review of patients receiving HBOT from April 2003 through December 2019 at our hospital was designed to describe clinical characteristics of patients and to identify adverse events during HBOT and within 24 hours after HBOT. Patients ≥ 40 years of age with a documented LVEF of ≤ 40% were included. Data are presented as mean (SD) [range] or counts, as appropriate. RESULTS: A total of 23 patients were included in the final analysis, 2 (1) [0-4] patients per year. Patients received 25 (19) [1-60] treatments. Two patients had an episode of acute decompensated heart failure possibly linked to HBOT. CONCLUSIONS: This study described the clinical characteristics of patients with reduced LVEF receiving HBOT and showed reassuring results, with a majority of patients with reduced LVEF tolerating HBOT well. Prospective research is required to more fully assess the risk. Copyright: This article is the copyright of the authors who grant Diving and Hyperbaric Medicine a non-exclusive licence to publish the article in electronic and other forms.
INTRODUCTION: Hyperbaric oxygen treatment (HBOT) is available to a wide spectrum of patients, many with significant co-morbidities. Considering its effects on cardiac physiology and reports of pulmonary oedema following exposure, concerns exist about the safety of patients with compromised cardiac function. Few studies have described adverse events occurring during HBOT and even fewer reports address events arising in the hours following HBOT. A relation between adverse events and cardiac function has not been established. As medical guidance is limited, we aimed to evaluate the risk for patients with reduced left ventricular ejection fraction (LVEF) receiving HBOT. METHODS: This retrospective chart review of patients receiving HBOT from April 2003 through December 2019 at our hospital was designed to describe clinical characteristics of patients and to identify adverse events during HBOT and within 24 hours after HBOT. Patients ≥ 40 years of age with a documented LVEF of ≤ 40% were included. Data are presented as mean (SD) [range] or counts, as appropriate. RESULTS: A total of 23 patients were included in the final analysis, 2 (1) [0-4] patients per year. Patients received 25 (19) [1-60] treatments. Two patients had an episode of acute decompensated heart failure possibly linked to HBOT. CONCLUSIONS: This study described the clinical characteristics of patients with reduced LVEF receiving HBOT and showed reassuring results, with a majority of patients with reduced LVEF tolerating HBOT well. Prospective research is required to more fully assess the risk. Copyright: This article is the copyright of the authors who grant Diving and Hyperbaric Medicine a non-exclusive licence to publish the article in electronic and other forms.
Authors: Mariusz Kozakiewicz; Joanna Slomko; Katarzyna Buszko; Wladyslaw Sinkiewicz; Jacek J Klawe; Malgorzata Tafil-Klawe; Julia L Newton; Pawel Zalewski Journal: Evid Based Complement Alternat Med Date: 2018-05-27 Impact factor: 2.629